SynthesisNature medicine2023
Genetically adjusted PSA levels for prostate cancer screening.
Erratum issuedOpen access · hybridAbstract readMeta-Analysis
In one paragraph
Synthesis in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
18.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Pooled it
- Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.Nature genetics · 2025Pooled it
- Evolving paradigms in prostate cancer screening: a decade of bibliometric insights and technological advancements.Frontiers in oncology · 2025Pooled it
- Body mass index threshold for obesity should be personalized based on polygenic score: Analysis of european and east asian biobanks.American journal of preventive cardiology · 2026Article
- Constructing Genetic Risk Scores: Robust Bayesian Approach through Projected Summary Statistics and Flexible Shrinkage.Journal of the American Statistical Association · 2026Article
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Polygenic risk scores for premagnetic resonance imaging risk stratification in men with clinically suspected prostate cancer.Journal of the National Cancer Institute · 2026Article
- Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome.Cell · 2026Article
- Characterizing the Uncertainty, Misclassification and Inconsistency of Polygenic Prediction.medRxiv : the preprint server for health sciences · 2026Article
- Germline polygenic score for prostate cancer aggressiveness.medRxiv : the preprint server for health sciences · 2026Article
- Clinical translation of polygenic scores for prostate cancer screening.Nature reviews. Urology · 2026Review
- Article
- Polygenic risk and germline genetics for prostate cancer in Asians: Where do we stand?Investigative and clinical urology · 2026Review
- Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.Nature cancer · 2026Article
- Estimating the heritability of longitudinal rate-of-change: genetic insights into PSA velocity in prostate cancer-free individuals.Biostatistics (Oxford, England) · 2026Article
- Prostate cancer risk-associated single-nucleotide polymorphisms impact the conformational dynamics of prostate-specific antigen.BMC biology · 2025Article
- The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules · 2025Review
- Variation in PSA Levels by Age, Adiposity, Race and Ethnicity, and Genetic Risk: Implications for Prostate Cancer Screening.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Article
- Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
23 authors at 11 institutions in 2 countries.
Linda KachuriDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3226-4727
Thomas J HoffmannDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6893-4449
Yu JiangDepartment of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
John P ShelleyDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
Kerry R SchafferVanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.ORCID 0000-0001-6538-9705
Neal D FreedmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.ORCID 0000-0002-4440-3368
Shengchao A LiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Ryder EasterlinBiological and Medical Informatics, University of California, San Francisco, San Francisco, CA, USA.
Phyllis J GoodmanFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cathee TillSWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ian ThompsonCHRISTUS Santa Rosa Medical Center Hospital, San Antonio, TX, USA.
Hans LiljaDepartments of Laboratory Medicine, Surgery and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5871-7846
Stephen K Van Den EedenDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.ORCID 0000-0002-2324-3393
Christopher A HaimanCenter for Genetic Epidemiology, Department of Population and Preventive Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
David V ContiCenter for Genetic Epidemiology, Department of Population and Preventive Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Robert J KleinDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-3539-5391
Jonathan D MosleyDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-6421-2887
Rebecca E GraffDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Rebecca.Graff@ucsf.edu.ORCID 0000-0003-0316-8303
John S WitteDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. jswitte@stanford.edu.ORCID 0000-0003-0146-1434
National Cancer Institute · USUniversity of California, San Francisco · USFred Hutch Cancer Center · USUniversity of Southern California · USVanderbilt University Medical Center · USIcahn School of Medicine at Mount Sinai · USKaiser Permanente · USMedical Center Hospital · USMemorial Sloan Kettering Cancer Center · USStanford University · USVanderbilt University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4MSWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MBMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6MLeveraging Prospective Cancer Epidemiology Cohorts and Novel Methods to Improve Polygenic Risk ScoresU01CA261339 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fei Chen, David V Conti · 2021 to 2026
$5.2MMedical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8MGenetic Predictors of Prostate Cancer SurvivalR01CA244948 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROBERT J. KLEIN · 2021 to 2026
$4.1MPrecision Prostate Cancer Screening with Genetically Adjusted Prostate-Specific Antigen LevelsR01CA241410 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI John S. Witte · 2020 to 2026
$3.7MImproving prostate cancer screening by integration of SNPs with blood biomarkersR01CA175491 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KLEIN, ROBERT J. · 2013 to 2018
$2.8MLeveraging common genetic variation to reduce misclassification of non-diseased individuals and unnecessary health care utilization attributable to surrogate biomarkersR01GM130791 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEY, JONATHAN DAVID · 2019 to 2023
$2.3MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MNCI NIH HHS K99 CA246076NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R00 CA246076NCI NIH HHS R01 CA175491NCI NIH HHS R01 CA241410NCI NIH HHS R01 CA244948NCI NIH HHS U01 CA261339NCI NIH HHS UG1 CA189974NIGMS NIH HHS R01 GM130791NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM067547NIGMS NIH HHS T32 GM152284NIH HHS S10 OD026880
Abstract
Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer-related PSA variation has potential to improve screening utility. In this study, we discovered 128 genome-wide significant associations (P < 5 × 10
Indexed as
Prostatic NeoplasmsBiopsyEarly Detection of CancerHumansMaleNeoplasm GradingProstate-Specific AntigenProstate-Specific Antigen
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.